S&P 500
5.018,39 -17,30 (-0,34%) Nasdaq
15.605,48 -52,34 (-0,33%) NIKKEI 225
38.276,31 +2,26 (+0,01%) Dólar/Euro
1,0719 +0,0001 (+0,01%) Petróleo Brent
83,92 +0,48 (+0,58%) Bitcoin EUR
53.571,65 -2.635,91 (-4,69%)
TetraLogic Pharmaceuticals Corporation (TLOG)
TetraLogic Pharmaceuticals Corporation
343 Phoenixville Pike
Malvern, PA 19355
United States
610 889 9900
https://www.tetralogicpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Yigong Shi Ph.D. | Co-Founder | N/A | N/A | 1969 |
| Sarah E. Frew | Director of Business & Commercial Development | N/A | N/A | N/A |
Descripción
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Gobierno corporativo
El ISS Governance QualityScore de TetraLogic Pharmaceuticals Corporation, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
